AbbVie, Enanta drug shows potential in hep C genotype 4 patients

November 11, 2014 3:28 PM

4 0

(Reuters) - AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

Also read: U.S. economy added 178,000 jobs in November; unemployment rate dropped to 4.6 percent

Read more

To category page

Loading...